Alumis Inc
ALMS26.190USD
-0.150-0.57%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
2.73BCap. mercado
PérdidaP/E TTM
Más Datos de Alumis Inc Compañía
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Información de Alumis Inc
Símbolo de cotizaciónALMS
Nombre de la empresaAlumis Inc
Fecha de salida a bolsaJun 28, 2024
Director ejecutivoBabler (Martin)
Número de empleados168
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 28
Dirección280 East Grand Avenue
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Teléfono16502316625
Sitio Webhttps://www.alumis.com/
Símbolo de cotizaciónALMS
Fecha de salida a bolsaJun 28, 2024
Director ejecutivoBabler (Martin)
Ejecutivos de Alumis Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
106.45K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+26750.00%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
+42800.00%
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
+28000.00%
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
25.45K
+25450.00%
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
+7064.00%
Dr. David M. Goldstein, Ph.D.
Dr. David M. Goldstein, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Roy C. Hardiman, J.D.
Mr. Roy C. Hardiman, J.D.
Chief Business and Strategy Officer
Chief Business and Strategy Officer
--
--
Ms. Sara Klein
Ms. Sara Klein
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
106.45K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+26750.00%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
+42800.00%
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
+28000.00%
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
25.45K
+25450.00%
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
+7064.00%
Desglose de ingresos
FY2025Q3
FY2025Q2
FY2025Q1
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
United States
2.07M
0.00%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: mié., 4 de feb
Actualizado: mié., 4 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Foresite Capital Management, LLC
13.27%
Ayur Maya Capital Management Company, L.P.
12.41%
Samsara BioCapital, LLC
5.20%
VenBio Partners LLC
3.79%
The Vanguard Group, Inc.
3.36%
Otro
61.97%
Accionistas
Accionistas
Proporción
Foresite Capital Management, LLC
13.27%
Ayur Maya Capital Management Company, L.P.
12.41%
Samsara BioCapital, LLC
5.20%
VenBio Partners LLC
3.79%
The Vanguard Group, Inc.
3.36%
Otro
61.97%
Tipos de accionistas
Accionistas
Proporción
Private Equity
32.11%
Investment Advisor
11.33%
Hedge Fund
9.51%
Venture Capital
7.36%
Investment Advisor/Hedge Fund
5.96%
Research Firm
0.67%
Individual Investor
0.66%
Bank and Trust
0.07%
Insurance Company
0.02%
Otro
32.33%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
211
79.11M
81.97%
+900.81K
2025Q3
210
78.21M
82.24%
-347.38K
2025Q2
186
78.54M
55.16%
+26.45M
2025Q1
129
40.48M
86.71%
-471.52K
2024Q4
110
40.33M
76.60%
+5.09M
2024Q3
85
35.23M
67.43%
+3.39M
2024Q2
30
30.28M
0.00%
+30.28M
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Foresite Capital Management, LLC
10.61M
10.91%
+580.09K
+5.79%
Nov 21, 2025
Ayur Maya Capital Management Company, L.P.
15.14M
15.57%
-1.00
-0.00%
Sep 30, 2025
Samsara BioCapital, LLC
5.13M
5.28%
+333.62K
+6.95%
Nov 20, 2025
VenBio Partners LLC
4.62M
4.75%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
4.03M
4.15%
+625.40K
+18.37%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.79M
3.9%
-17.42K
-0.46%
Sep 30, 2025
Nextech Invest, Ltd.
2.92M
3%
--
--
Sep 30, 2025
Cormorant Asset Management, LP
2.15M
2.21%
--
--
Sep 30, 2025
SR One Capital Management, LP
1.96M
2.02%
--
--
Sep 30, 2025
OrbiMed Advisors, LLC
1.93M
1.98%
--
--
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
ProShares Ultra Nasdaq Biotechnology
0.09%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Value ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
Ver más
ProShares Ultra Nasdaq Biotechnology
Proporción0.09%
iShares Micro-Cap ETF
Proporción0.05%
Invesco Nasdaq Biotechnology ETF
Proporción0.05%
iShares Biotechnology ETF
Proporción0.03%
iShares Russell 2000 Value ETF
Proporción0.03%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.03%
ProShares Hedge Replication ETF
Proporción0.02%
iShares Russell 2000 ETF
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
